Free tool
FAERS Monitor: Pitocin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018261 or its brand name (Pitocin, Oxytocin). Reports on generic versions are filed under their own applications.
Reports
3,047
Serious
2,695
88% of reports
Hospitalization
914
Death reported
155
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- foetal exposure during pregnancy456
- maternal exposure during pregnancy441
- drug ineffective402
- exposure during pregnancy366
- premature baby209
- hypotension196
- off label use191
- premature delivery163
- postpartum haemorrhage155
- drug exposure during pregnancy143
- maternal exposure during delivery137
- caesarean section105
- low birth weight baby104
- nausea101
- dyspnoea95
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 40 |
| 2005 | 33 |
| 2006 | 61 |
| 2007 | 44 |
| 2008 | 71 |
| 2009 | 56 |
| 2010 | 87 |
| 2011 | 75 |
| 2012 | 79 |
| 2013 | 104 |
| 2014 | 128 |
| 2015 | 128 |
| 2016 | 196 |
| 2017 | 149 |
| 2018 | 182 |
| 2019 | 144 |
| 2020 | 213 |
| 2021 | 200 |
| 2022 | 237 |
| 2023 | 298 |
| 2024 | 203 |
| 2025 | 173 |
| 2026 | 144 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,112 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| maternal exposure during deliverySignal | 137 | 1108.3 | 928.7 | 129,666 |
| postpartum haemorrhageSignal | 155 | 897.6 | 762.2 | 122,075 |
| low birth weight babySignal | 104 | 91.5 | 75.7 | 9,105 |
| premature deliverySignal | 163 | 71.4 | 61.4 | 11,133 |
| caesarean sectionSignal | 105 | 62.8 | 52.0 | 6,268 |
| premature babySignal | 209 | 48.3 | 42.3 | 9,573 |
| exposure during pregnancySignal | 366 | 40.9 | 37.1 | 14,159 |
| foetal exposure during pregnancySignal | 456 | 38.9 | 35.8 | 16,787 |
| maternal exposure during pregnancySignal | 441 | 34.3 | 31.5 | 14,223 |
| drug exposure during pregnancySignal | 143 | 29.1 | 24.8 | 3,849 |
| hypotensionSignal | 196 | 6.8 | 5.9 | 963 |
| drug ineffectiveSignal | 402 | 2.1 | 1.9 | 248 |
| off label use | 191 | 1.5 | 1.3 | 33 |
| dyspnoea | 95 | 1.2 | 1.0 | 2 |
| nausea | 101 | 0.9 | 0.7 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.